The new NAFTA could thwart president’s promise to lower prescription drug costs

Analytics 23:41 08.10.2018
President Trump has declared lowering our nation’s drug costs a high priority. But his renegotiated North American Free Trade Agreement, which has now been rebranded by Trump as the US-Mexico-Canada Agreement (USMCA), will actually prevent him from reducing the exorbitant costs of prescription drugs for America’s patients. That’s because a provision of proposed agreement would increase the monopoly period for certain high-priced brand name biologic medicines while banning competition from lower-priced alternatives.
 
Among other protections for Big Pharma, the USMCA would ensure that pharmaceutical companies have at least 10 years of exclusivity for their biologic medicines in Mexico and Canada before lower-cost, FDA-approved clinically equivalent alternatives known as biosimilars can compete. Far from rewarding innovation, the agreement preserves and strengthens brand name pharmaceuticals’ monopolistic stranglehold on the market, allowing them to keep prices high and failing to require reinvestment in the development of new, life-saving cures.
 
When the president announced his plans to reduce prescription drug prices, he emphasized the need for a more competitive marketplace for prescription drugs. In no area is competitive relief needed more than in the biologics market. According to a recent report by the prescription drug analytics firm IQVIA, the class of drug that includes branded biologics represents roughly 2 percent of the prescriptions in the U.S., but account for a disproportionate 26 percent of total drug spending.
 
The American experience with biosimilars has shown significant promise toward lowering prices as it increases patient access. For example, the current list price of Amgen’s Neupogen, a biologic that increases white blood cell count during a course of chemotherapy, is roughly $2,500. There is one biosimilar to Neupogen currently on the market, Zarxio from Sandoz, whose list price is roughly $750, less than a third of Neupogen’s. Because a patient’s out-of-pocket costs are directly linked to the list price of the product, these lower prices mean significant savings for patients and payers alike.
 
A robust biosimilars market is vital to spur future innovation while ensuring health care costs benefit from the competition of lower-priced alternatives. America’s patients currently have access to only four biosimilar drugs, but more than 40 are available in Europe, where increased access to biosimilar drugs has lowered treatment costs by an estimated 40 percent. Savings from FDA-approved biosimilars could mean millions of patients in the U.S. would no longer have to risk bankruptcy or their quality of life to afford the life-saving medicines they need.
 
A 10-year exclusivity provision as is presented in the new NAFTA agreement—together with other barriers to generic and biosimilar entry that were proposed in the TPP— would block fair competition and ensure that big pharmaceutical companies can keep their prices high if they choose. And as a binding treaty, USMCA could make it much more difficult for Congress to increase competition from biosimilars by adjusting the exclusivity period for brand name drugs.
 
So who would bear the ultimate costs? Patients, because they would not be able to benefit from lower-cost biosimilars the way they have from affordable generics. The top 11 most promising biosimilars in production alone are projected to create $250 billion in savings in the next 10 years. Yet, as FDA Commissioner Dr. Scott Gottlieb has stated, the biosimilars market is already being stifled by unfair market restraints, and few biosimilars are actually making it to market. The USMCA proposal would further hamper this nascent market.
 
We have already seen what the impact of generic drug competition can have for patients. Over the last 10 years, the use of generic drugs has resulted in a staggering $1.67 trillion in savings, and it is estimated that drug prices are reduced by 60 percent a year after the introduction of a generic drug. And generics benefit taxpayers too – these drugs save Medicare and Medicaid billions of dollars every year.
 
According to a recent Kaiser Health tracking poll, a majority of Americans think the increasing costs of prescriptions should be a top priority for the Trump administration and Congress to address, and a full 90 percent consider the issue important. Further, 72 percent of Americans across party lines think that prescription drug companies have too much influence in Washington.
 
The Trump administration and members of Congress (many of whom are currently facing a competitive midterm election) should take heed of these numbers. America’s patients are tired of their prescriptions costing so much, and they want their leaders to do something about it. Using USMCA to supersede any U.S. efforts to reduce drug prices is not only counter to the will of the American people but to the Trump administration’s own doctrine of “America First.”
 
The president’s pledge to reduce prescription drug costs and free up the marketplace is an admirable goal. However, the inclusion of 10-year exclusivity protections, as well as other roadblocks to generic and biosimilar competition to benefit big pharmaceutical companies, in the proposed USMCA agreement would stifle any efforts to reduce drug prices and restore market freedoms for a decade or more.
 
This is something that the America’s patients can’t afford, which is why everyone should call on the Trump administration and Congress to remove additional monopoly time for brand-name drugs from any new free trade agreement.
Azerbaijan takes measures to turn Khankandi into safe city - VİDEO

News line

Russia prepares for new offensive in May-June l – says Zelensky
23:52 28.03.2024
Russian investigators have evidence of Ukraine link to Crocus terrorists
22:24 28.03.2024
Committee members of the EU Council will visit the South Caucasus region
19:48 28.03.2024
Bayern to pay Thomas Tuchel 12M euro compensation
Bayern to pay Thomas Tuchel 12M euro compensation
19:00 28.03.2024
Crocus City Hall terrorists took drugs before attack - law enforcement agencies
Crocus City Hall terrorists took drugs before attack - law enforcement agencies
18:33 28.03.2024
Azerbaijan, UN Development Program mull future co-op
18:00 28.03.2024
An Independent Trade Union Established within International Eurasia Press Fund - First in NGO sector - PHOTOS
17:39 28.03.2024
Italian PM condemns Macron for idea of sending troops to Ukraine
Italian PM condemns Macron for idea of sending troops to Ukraine
17:23 28.03.2024
Azerbaijan lends clarity to color requirement for taxis
17:02 28.03.2024
Isaac Herzog: Israel has no greater friend than US, and US has no greater friend than Israel
Isaac Herzog: Israel has no greater friend than US, and US has no greater friend than Israel
16:45 28.03.2024
Nigerian army eliminates over 200 militants in 2 weeks
16:30 28.03.2024
Armored Vehicle Coalition for Ukraine launched in Poland
Armored Vehicle Coalition for Ukraine launched in Poland
16:15 28.03.2024
Russia strengthens transport security measures after terror attack at Crocus City Hall
Russia strengthens transport security measures after terror attack at Crocus City Hall
15:55 28.03.2024
Türkiye plays an important role between Russia and Ukraine - says political scientist Ismail Cingoz
15:45 28.03.2024
2 schoolchildren detained in France on suspicion of sending bomb threats
15:35 28.03.2024
Ski resort in Georgia hit by avalanche
Ski resort in Georgia hit by avalanche
15:26 28.03.2024
Another protest against French colonialism held in New Caledonia, Azerbaijani flag raised
Another protest against French colonialism held in New Caledonia, Azerbaijani flag raised
15:15 28.03.2024
Media: US did not transfer all information about terrorist attack in Crocus City Hall to Russia
15:00 28.03.2024
Movement ‘Together’ calls on Armenia’s parliamentary forces to express vote of no confidence in Pashinyan
14:41 28.03.2024
Azerbaijan to participate in international trade fair in Istanbul
Azerbaijan to participate in international trade fair in Istanbul
14:32 28.03.2024
Le Pen accuses French government of fraud
14:22 28.03.2024
Armenian Government Grapples with Internal Division on Village Return Issue - Ishkhan Verdiyan talks on Ednews
14:12 28.03.2024
Ammunition found along route of Crocus City Hall terrorists
Ammunition found along route of Crocus City Hall terrorists
13:41 28.03.2024
Expert Ilyas Huseynov Predicts Peaceful Return of these territories to Azerbaijan
13:20 28.03.2024
Azerbaijan weather forecast for March 29
Azerbaijan weather forecast for March 29
12:55 28.03.2024
Russian MFA concerned about upcoming Armenia-US-EU meeting
12:23 28.03.2024
Secret Points of Pashinyan's Meeting with French Representative: Is Peace Agreement Signing Imminent?
12:00 28.03.2024
Armenia announces recruitment of border guards to work at Zvartnots
Armenia announces recruitment of border guards to work at Zvartnots
11:47 28.03.2024
The US-Armenia-EU Joint Conference is a part of the pressure plan on Azerbaijan - MP Konul Nurullayeva
11:30 28.03.2024
Azerbaijan’s central bank reduces discount rate
Azerbaijan’s central bank reduces discount rate
11:23 28.03.2024
CSTO chief: ‘Yerevan doesn’t participate in our work, but there are no statements about suspension’
11:13 28.03.2024
Ammunition found in Khankandi
Ammunition found in Khankandi
11:00 28.03.2024
Russia had been aware of preparation for terrorist attack at Crocus - says intelligience chief
10:46 28.03.2024
Scholtz reveals date of his last telephone conversation with Putin
Scholtz reveals date of his last telephone conversation with Putin
10:33 28.03.2024
Head of the SSS: France is inciting Armenia to a new war
10:21 28.03.2024
Are we in the brink of World War III? - Pundit talks on Ednews
10:10 28.03.2024
Azerbaijan's National Security: Reflecting on 105 Years of Defending Sovereignty
09:55 28.03.2024
Hikmat Hajiyev: Rasmussen fell in forgetfulness to attach payment to his report
09:35 28.03.2024
Hand grenades found in Kalbajar
09:25 28.03.2024
Titanic 'door' prop that kept Rose alive sells for $718,750
Titanic 'door' prop that kept Rose alive sells for $718,750
08:50 28.03.2024
Hamısı